MCID: CTN004
MIFTS: 41

Cutaneous Fibrous Histiocytoma malady

Categories: Rare diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Cutaneous Fibrous Histiocytoma

Aliases & Descriptions for Cutaneous Fibrous Histiocytoma:

Name: Cutaneous Fibrous Histiocytoma 12 50 14 69
Dermatofibroma 12 50 52
Fibrohistiocytic Tumor 12 69
Benign Cutaneous Fibrous Histiocytoma 12
Dermatofibroma, No Icd-O Subtype 12
Fibrous Histiocytoma of Skin 12
Sclerosing Angioma of Skin 12
Fibrohistiocytic Neoplasm 12
Fibrous Xanthoma of Skin 12
Pleomorphic Fibroma 12
Dermatofibroma Nos 12
Sclerosing Angioma 12

Classifications:



Summaries for Cutaneous Fibrous Histiocytoma

NIH Rare Diseases : 50 dermatofibroma is a common benign skin nodule. it frequently develops on the extremities (most often the lower legs). although it is generally not associated with any signs or symptoms, some affected people may experience itching and/or tenderness. dermatofibromas are found in people of all ages and ethnicity and are more commonly diagnosed in women than men. the underlying cause of dermatofibroma is currently unknown. treatment is generally not required, but if symptoms are present, the lesion can be surgically removed. last updated: 3/19/2017

MalaCards based summary : Cutaneous Fibrous Histiocytoma, also known as dermatofibroma, is related to histiocytoma and malignant skin fibrous histiocytoma. An important gene associated with Cutaneous Fibrous Histiocytoma is F13A1 (Coagulation Factor XIII A Chain), and among its related pathways/superpathways are Cytoskeletal Signaling and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include skin and monocytes, and related phenotypes are cardiovascular system and muscle

Related Diseases for Cutaneous Fibrous Histiocytoma

Diseases related to Cutaneous Fibrous Histiocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
id Related Disease Score Top Affiliating Genes
1 histiocytoma 11.5
2 malignant skin fibrous histiocytoma 11.3
3 sclerosing hemangioma 11.1
4 undifferentiated pleomorphic sarcoma 10.9
5 fibrous histiocytoma 10.4
6 inflammatory linear verrucous epidermal nevus 10.3 DES VIM
7 reticulohistiocytic granuloma 10.3 DES F13A1
8 typical urticaria pigmentosa 10.3 F13A1 S100B
9 cortical blindness 10.3 F13A1 VIM
10 lymphomatous thyroiditis 10.3 DES VIM
11 hematologic cancer 10.3 F13A1 VIM
12 marfanoid hypermobility syndrome 10.3 DES VIM
13 adult endodermal sinus tumor 10.2 DES VIM
14 tanycytic ependymoma 10.2 DES VIM
15 intrahepatic bile duct cystadenoma 10.2 DES S100B
16 lupus - neurological sequelae 10.2 S100B VIM
17 ovarian cystadenoma 10.2 DES S100B
18 liver angiosarcoma 10.2 DES VIM
19 male reproductive system disease 10.2 DES VIM
20 jejunal neuroendocrine tumor 10.2 S100B VIM
21 foix-alajouanine syndrome 10.2 DES S100B
22 petrous apex meningioma 10.2 DES VIM
23 microinvasive cervical squamous cell carcinoma 10.2 S100B VIM
24 dystrophic epidermolysis bullosa, nails only 10.2 ACTC1 F13A1
25 subglottis verrucous carcinoma 10.2 S100B VIM
26 clear cell ependymoma 10.2 S100B VIM
27 behcet's syndrome arthropathy 10.2 S100B VIM
28 secondary adrenal insufficiency 10.2 ACTC1 F13A1
29 sternum cancer 10.2 S100B VIM
30 anal gland neoplasm 10.2 DES VIM
31 bone deterioration disease 10.2 DES S100B
32 aneurysm of sinus of valsalva 10.2 S100B VIM
33 carbon monoxide-induced parkinsonism 10.2 ACTC1 DES
34 lymphomatoid papulosis 10.2 ACTC1 VIM
35 vagina leiomyosarcoma 10.2 ACTC1 DES
36 chest wall parachordoma 10.2 ACTC1 VIM
37 fibroma 10.2
38 congenital muscular dystrophy with hyperlaxity 10.2 DES VIM
39 stomach diverticulosis 10.2 S100B VIM
40 acute generalized exanthematous pustulosis 10.2 ACTC1 S100B
41 chiasmal syndrome 10.2 ACTC1 S100B
42 rohhad 10.2 COL1A1 PDGFB
43 episodic ataxia 10.2 ACTC1 DES
44 hemangioma of liver 10.2 ACTC1 S100B
45 dentin dysplasia with sclerotic bones 10.2 F13A1 S100B
46 pustulosis palmaris et plantaris 10.2 ACTC1 DES
47 testicular granulosa cell tumor 10.2 ACTC1 VIM
48 gastrointestinal system cancer 10.2 S100B VIM
49 spasmodic dystonia 10.2 PDGFB VIM
50 lymphangiosarcoma 10.2 ACTC1 VIM

Graphical network of the top 20 diseases related to Cutaneous Fibrous Histiocytoma:



Diseases related to Cutaneous Fibrous Histiocytoma

Symptoms & Phenotypes for Cutaneous Fibrous Histiocytoma

MGI Mouse Phenotypes related to Cutaneous Fibrous Histiocytoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.43 ACTC1 COL1A1 DES F13A1 PDGFB VIM
2 muscle MP:0005369 9.02 ACTC1 COL1A1 DES PDGFB VIM

Drugs & Therapeutics for Cutaneous Fibrous Histiocytoma

Drugs for Cutaneous Fibrous Histiocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
6
Dactinomycin Approved Phase 3 50-76-0 2019 457193
7
Epirubicin Approved Phase 3 56420-45-2 41867
8
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
9
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
10
Lenograstim Approved Phase 3,Phase 2 135968-09-1
11
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
13 Alkylating Agents Phase 3,Phase 2,Phase 1
14 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
16 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
17 Isophosphamide mustard Phase 3,Phase 2,Phase 1
18 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
19 Anti-Infective Agents Phase 3,Phase 2,Phase 1
20 Antimitotic Agents Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
22 Antirheumatic Agents Phase 3,Phase 2,Phase 1
23 Etoposide phosphate Phase 3,Phase 2
24 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
25 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
26
Indinavir Approved Phase 2 150378-17-9 5362440
27
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
28
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
29
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
30
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
31
Bevacizumab Approved, Investigational Phase 2 216974-75-3
32
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
33
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
34
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
35
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
36
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
37
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
38
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
39
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
40
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
41
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
43
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
44
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
45
leucovorin Approved, Nutraceutical Phase 2 58-05-9 54575, 6560146 143
46
Docetaxel Approved May 1996, Investigational Phase 2,Phase 1 114977-28-5 148124 9877265
47
Camptothecin Experimental Phase 2 7689-03-4
48 Anti-HIV Agents Phase 2
49 Anti-Retroviral Agents Phase 2
50 Antiviral Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 62)
id Name Status NCT ID Phase
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
3 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3
4 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
5 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3
7 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3
8 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
10 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
11 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
12 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
13 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3
14 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
15 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2
16 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
17 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2
18 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2
19 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2
20 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2
21 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2
22 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
23 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2
24 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2
25 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2
26 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2
27 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2
28 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2
29 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2
30 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2
31 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2
32 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2
33 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2
34 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2
35 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
36 To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Recruiting NCT01962103 Phase 1, Phase 2
37 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
38 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2
39 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2
40 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2
41 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2
42 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Active, not recruiting NCT01653028 Phase 2
43 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Not yet recruiting NCT03123276 Phase 1, Phase 2
44 Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Not yet recruiting NCT02923778 Phase 2
45 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2
46 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
47 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1
48 Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors Completed NCT00413322 Phase 1
49 Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00030784 Phase 1
50 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1

Search NIH Clinical Center for Cutaneous Fibrous Histiocytoma

Genetic Tests for Cutaneous Fibrous Histiocytoma

Anatomical Context for Cutaneous Fibrous Histiocytoma

MalaCards organs/tissues related to Cutaneous Fibrous Histiocytoma:

39
Skin, Monocytes

Publications for Cutaneous Fibrous Histiocytoma

Articles related to Cutaneous Fibrous Histiocytoma:

(show all 15)
id Title Authors Year
1
Metastasizing "benign" cutaneous fibrous histiocytoma: a clinicopathologic analysis of 16 cases. ( 23426120 )
2013
2
Atypical cutaneous fibrous histiocytoma: an unusual and misleading variant of fibrous histiocytoma. ( 22937387 )
2011
3
A unique biphasic variant of cutaneous fibrous histiocytoma with a storiform pattern and intralesional pigmented melanocytes: "storiform melano-fibrous histiocytoma". ( 18474466 )
2008
4
A study of monocytic and dendritic cell markers in benign cutaneous fibrous histiocytoma (dermatofibroma). ( 18462367 )
2008
5
The value of immunohistochemistry in atypical cutaneous fibrous histiocytoma. ( 15365367 )
2004
6
Clonal analysis of cutaneous fibrous histiocytoma (dermatofibroma). ( 12139632 )
2002
7
Aneurysmal fibrous histiocytoma: an unusual variant of cutaneous fibrous histiocytoma. ( 10461644 )
1999
8
Recurring atypical ("pseudosarcomatous") cutaneous fibrous histiocytoma. ( 9649666 )
1998
9
Cutaneous fibrous histiocytoma. ( 9158319 )
1997
10
Cutaneous fibrous histiocytoma with osteoclast-like giant cells. ( 8863988 )
1996
11
Cellular benign fibrous histiocytoma. Clinicopathologic analysis of 74 cases of a distinctive variant of cutaneous fibrous histiocytoma with frequent recurrence. ( 8017561 )
1994
12
Palisading cutaneous fibrous histiocytoma. An immunohistochemical study demonstrating differentiation from dermal dendrocytes. ( 8311187 )
1993
13
Atypical cutaneous fibrous histiocytoma. ( 3028197 )
1986
14
Atypical, cutaneous fibrous histiocytoma with early metastasis. ( 3012378 )
1986
15
Palisading cutaneous fibrous histiocytoma. ( 3029199 )
1986

Variations for Cutaneous Fibrous Histiocytoma

Expression for Cutaneous Fibrous Histiocytoma

Search GEO for disease gene expression data for Cutaneous Fibrous Histiocytoma.

Pathways for Cutaneous Fibrous Histiocytoma

Pathways related to Cutaneous Fibrous Histiocytoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.98 ACTC1 DES VIM
2 11.03 PDGFB S100B VIM
3
Show member pathways
10.91 DES VIM
4 10.66 ACTC1 DES VIM
5 10.3 COL1A1 PDGFB

GO Terms for Cutaneous Fibrous Histiocytoma

Cellular components related to Cutaneous Fibrous Histiocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.55 ACTC1 COL1A1 PDGFB S100B SERPINA3
2 extracellular matrix GO:0031012 9.43 COL1A1 PDGFB VIM
3 blood microparticle GO:0072562 9.13 ACTC1 F13A1 SERPINA3
4 platelet alpha granule lumen GO:0031093 8.8 F13A1 PDGFB SERPINA3

Biological processes related to Cutaneous Fibrous Histiocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intermediate filament organization GO:0045109 9.16 DES VIM
2 platelet degranulation GO:0002576 9.13 F13A1 PDGFB SERPINA3
3 muscle filament sliding GO:0030049 8.8 ACTC1 DES VIM

Molecular functions related to Cutaneous Fibrous Histiocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.02 COL1A1 DES PDGFB S100B VIM
2 platelet-derived growth factor binding GO:0048407 8.96 COL1A1 PDGFB

Sources for Cutaneous Fibrous Histiocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....